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Abstract
The cyclin dependent kinase 5 (Cdk5)/p35 complex is essential for regulation of cell survival during
development and in models of neuronal excitotoxicity. Dysregulation of Cdk5, by cleavage of its
neuronal specific activators p35 and p39, has been implicated in various neurodegenerative disorders
such as Alzheimer's disease, however targets of the complex that regulate neuronal survival
physiologically and/or during pathogenesis are largely unknown. Since hypoxia is a key feature in the
pathogenesis of several neuronal disorders we investigated a role for Cdk5/p35 in the neuronal hypoxic
response. Our data shows that hypoxia modulates the p35/Cdk5 complex in primary cortical neurons at
the transcriptional and protein level. Furthermore hypoxic induction of Cdk5 activity correlates with
Hif-1α stabilisation, and direct interaction between these proteins can occur. Importantly, we
demonstrate that Cdk5-mediated signaling is involved in Hif-1α stabilisation since inhibition of Cdk5 by
roscovitine abrogates Hif-1α accumulation and induces cell death. Taken together our results show that
the Cdk5/p35 complex may significantly contribute to modulation of Hif-1α stabilisation and impact
neuronal survival during oxygen deprivation. Thus this study highlights a new hypoxia-mediated
signaling pathway and implicates the cytoskeleton as a potential regulator of Hif-1α. Section: Cellular
and Molecular Biology of Nervous Systems.
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2ABSTRACT
The cyclin dependent kinase 5 (Cdk5)/p35 complex is essential for regulation of cell
survival during development and in models of neuronal excitotoxicity. Dysregulation
of Cdk5, by cleavage of its neuronal specific activators p35 and p39, has been
implicated in various neurodegenerative disorders such as Alzheimer’s disease,
however targets of the complex that regulate neuronal survival physiologically and/or
during pathogenesis are largely unknown. Since hypoxia is a key feature in the
pathogenesis of several neuronal disorders we investigated a role for Cdk5/p35 in the
neuronal hypoxic response. Our data shows that hypoxia modulates the p35/Cdk5
complex in primary cortical neurons at the transcriptional and protein level.
Furthermore hypoxic induction of Cdk5 activity correlates with Hif-1α stabilisation,
and direct interaction between these proteins can occur. Importantly, we demonstrate
that Cdk5-mediated signaling is involved in Hif-1α stabilisation since inhibition of
Cdk5 by roscovitine abrogates Hif-1α accumulation and induces cell death. Taken
together our results show that the Cdk5/p35 complex may significantly contribute to
modulation of Hif-1α stabilisation and impact neuronal survival during oxygen
deprivation. Thus this study highlights a new hypoxia-mediated signaling pathway
and implicates the cytoskeleton as a potential regulator of Hif-1α. 
Section: Cellular and Molecular Biology of Nervous Systems
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3INTRODUCTION
Efficient oxygen delivery to brain tissues is essential for cell survival and normal
brain function. Hypoxia, an important stimulus characterising a wide variety of
physiological events, also contributes significantly to progression of pathogenesis and
widespread diseases including cancer, stroke and neurodegenerative disorders.
At the molecular level, a large percentage of hypoxic/ischemic responses are
controlled by the transcription factor hypoxia-inducible factor-1 (Hif-1) (Fandrey et
al., 2006; Hopfl et al., 2003). Hif-1 is a heterodimer composed of an oxygen-
dependent Hif-1α subunit and a constitutively expressed Hif-1β subunit. Under
normoxic conditions Hif-1α  is hydroxylated, ubiquinated and rapidly degraded by
proteasome 26S. Upon hypoxia, stabilised Hif-1α translocates to the nucleus and
dimerises with Hif-1β ultimately leading to increased transcription of a number of
gene products. Post translational modifications including ubiquitination, sumoylation
as well as phosphorylation all contribute to the modulation of Hif-1 expression and
activity (Koh et al., 2008). Hypoxic signal transduction may require
kinase/phosphatase activity since treatment of cells with genistein, a tyrosine kinase
inhibitor, or sodium fluoride, a serine/threonine phosphatase inhibitor, blocks
hypoxia-induced HIF-1α  expression. Furthermore recent reports point to the
involvement of the cytoskeleton and/or cytoskeleton regulatory proteins in Hif-1
regulation. Microtubule-targeting agents down-regulate Hif-1 in cancer cell lines
exposed to hypoxia (Escuin et al., 2005) and a role for the cytoskeleton-regulating
protein, Rac1, in the modulation of Hif-1α in a carcinoma cell line was recently
reported (Gorlach et al., 2003; Hirota et al., 2004).   
In this study we have focused on the serine/threonine protein kinase Cdk5, a neuronal
cytoskeleton regulatory protein, as a potential modulator of the neuronal hypoxic
4response. Cdk5 together with its neuronal specific activators, p35 and p39, not only is
a key regulator of the neuronal cytoskeleton but also an important determinant of
neuronal death/survival signals. The substrate specificity of the Cdk5/p35 complex
requires the K(S/T)PX(K/R) motif where S or T (serine or threonine respectively) are
the candidate residues for phosphorylation (Sharma et al., 1998). A number of
substrates ranging from cytoskeletal proteins to transcription factors have been
identified (Cheung and Ip, 2004).
A role for Cdk5 has been reported in a number of neurodegenerative disorders
including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis
(Lau et al., 2002; Nguyen et al., 2001) establishing the importance of the protein in
neuronal survival during disease progression. Increased p35 levels and Cdk5 activity
in neurons was also reported after middle cerebral artery occlusion (Hayashi et al.,
1999) as well as in human stroke tissue (Mitsios et al., 2007) implicating a role for the
complex in the neuronal response to ischemic injury.
To explore the possibility that hypoxia could alter the activity of the cytoskeleton
regulatory Cdk5/p35 complex, and whether Cdk5 itself may contribute to the neuronal
response to oxygen deprivation, we employed an in vitro model of primary mouse
neurons. We show that oxygen deprivation indeed modulates the Cdk5/p35 complex,
which in turn modifies the neuronal hypoxic response via modulation of Hif-1
mediated pathways.
MATERIALS AND METHODS
All experiments were performed in accordance with Swiss animal protection laws and
University of Zürich institutional guidelines for animal experimentation.
5Primary neuronal cultures. Primary neuronal cultures were obtained from the cerebral
cortex of C57Bl/6J mice gestational stage E14 as previously described (Ogunshola et
al., 2002). Dissected cortices were dissociated in Hank’s buffered salt solution
(HBSS) containing trypsin and DNase I for 5min at 37°C. Neurons were seeded on
poly-L-lysine coated petri dishes (3 X 106 cells per 100mm dish) in DMEM medium
containing: B27 supplement (1X), albumax (0.25g/ml), sodium pyruvate (1%) and
100U/ml streptomycinpenicillin, (GIBCO, Invitrogen, AG, Switzerland). Neurons
were maintained in culture for 6 days (6DIV) at normal atmosphere (21%O2) in a
humidified incubator at 37°C.
Hypoxic experiments and inhibitor treatment. Hypoxic experiments were performed
in a purpose-built glove-box chamber ( In vivo 400, RUSKINN Technologies,
Guiseley, UK) maintained at 37°C with 5% CO2. Neurons were exposed to 1% O2
for different periods of time and cell harvesting was performed within the chamber
(i.e. without reoxygenation of samples).  Normoxic control cultures were maintained
at 21% O2. For reoxygenation experiments neurons were exposed to 1% O2 for 2h
and were subsequently returned to 21% O2 for 4h before cell harvesting. Cdk5
activity was inhibited by direct application of 20µM roscovitine (Calbiochem,
Lucerne, Switzerland) to neuronal cultures immediately prior to hypoxic exposure.
ATP measurements. An ATP bioluminescent assay kit (Sigma, Buchs, Switzerland)
was used according to manufacturer’s instructions. Following hypoxia cells were
lysed in lysis buffer (150mM NaCl, 50mM Tris, 1% Triton X-100, 1% NP-40)
supplemented with protease inhibitors (Roche, Basel, Switzerland) for 10 min
followed by 10 min centrifugation at 16’000 rcf. The supernatant was mixed with 5%
6TCA (1:1 v/v) to block residual ATPase activity and luminescence was measured
using a Berthold luminometer (Detection systems GmbH, Pforzheim, Germany). ATP
amounts were determined from a standard curve and total amount of ATP was
normalised to total protein concentrations.
Assessment of cell death. Neuronal cell death was quantitatively assessed using a
colorimetric assay for detection of lactate dehydrogenase (LDH) release in the
medium according to the manufacturer’s instructions (Roche, Penzberg, Germany).
Real-Time PCR (RT-PCR). Total RNA was isolated using TRIzol reagent (Invitrogen
AG, Switzerland) according to the manufacturer instructions. 2µg RNA was used for
cDNA synthesis using the QuantiTect Reverse Transcription kit (Qiagen AG,
Hombrechtikon, Switzerland). Analysis was performed with 1µl of the final cDNA
mix using mouse-specific Taq-Man-based gene expression assays (Applied
Biosystems). The following assays were used in an ABI 7500 RT-PCR thermocycler
(Applied Biosystems, Foster City, CA): 28sRNA (catalog no.: Mm00508318_m1),
p35 (catalog no.: Mm00438148_s1), Cdk5 (catalog no.: Mm00432437_m1), Hif-
1α (catalog no.:Mm00468869_m1), Glut-1 (catalog no.: Mm00441473_m1),  Epo
(catalog no.: Mm00433126_m1). Data were normalised to 28s RNA and normoxic
controls. All reactions were run in duplicate and at least three independent
experiments were performed.
Western Blot. Cells were lysed in lysis buffer (150mM NaCl, 50mM Tris, 1% Triton
X- 100, 1% NP-40) for 10min and centrifuged at 16’000 rcf for 10 min (4°C) and the
supernatant collected. 75µg of protein were loaded on SDS-polyacrylamide gels and
7transferred to nitrocellulose membranes. Membranes were incubated with anti-p35
(C-19, 1:500, Santa Cruz, CA, USA), anti-Cdk5 (C-8, 1:250, Santa Cruz, CA, USA),
anti Hif-1α (NB 100-479, 1:1000, NOVUS, Littleton, USA) and anti-Tuj1 (SIG 3840,
1:7000, COVANCE, Berkeley, California). Following washes, membranes were
incubated with a secondary HRP-conjugated antibody for 1 hour at room temperature.
All blots were normalised to Tuj-1 and normoxic controls and at least 3 independent
experiments were performed. Results were quantified by densitometry using BioRad
Quantity One software (BioRad laboratories AG, Switzerland).
Immunoprecipitation. Neurons were lysed in IP buffer A (50mM Tris, 150mM NaCl,
5mM EDTA, 0.5% NP40) containing protease inhibitors. Immunoprecipitation was
performed using 2µg of either Hif-1α or Cdk5 antibody for 2 hours at 4°C. Next 50µl
of washed A/G sepharose beads (Sigma) were added to the lysate-antibody mix and
rotated for 1 hour at 4°C. Sepharose beads were then recovered by centrifugation and
washed 3 times with cold TBS. The beads were resuspended in laemmli buffer and
heated to 80°C for 2 mins before loading supernatant samples on a 10% SDS page
gel. Western blot analysis was subsequently performed as above.
Cdk5 kinase assay. 50µg of whole cell protein were incubated with 2µg of anti-Cdk5
(C-8, Santa Cruz, CA, USA) for 2h and precipitated with protein A-sepharose beads
(Amersham, Buckinghamshire, UK) for 1h at 4°C. Immunoprecipitated complexes
were incubated with 10 µg of histone H1 and 1µCi of 32P in kinase buffer (10mM
Tris, 1mM DTT, 2mM EGTA, 10mM MgCl2, 20mM ATP) for 30min at room
temperature. The reaction was stopped with the addition of Laemmli buffer and
8samples were denaturated at 95°C for 5 min, then loaded on a 15% SDS-PAGE gel.
After running, the gel was dried d
within a slab gel dryer system (Witec AG, Littau) at 80°C for 2 hours then exposed to
a phosphoscreen and visualised using a BioRad Molecular Imager FX.
Immunocytochemistry. Neurons were plated on coverslips in 24 well plates (70,000
cells per well), grown for 6 days and then subjected to hypoxia. Cultures were fixed
with 4% paraformaldehyde in PBS (pH 7.4) for 5min at room temperature then
permeabilised in 0.1%Triton X-100 for 1min and blocked with 5% normal goat. Cells
were then incubated with the primary antibodies anti-p35 (C19, 1:500, Santa Cruz,
CA) or anti-Cdk5 (C8,1:500, Santa Cruz, CA) overnight at 4°C. Secondary antibody
to p35 was Cy3 (Jackson ImmunoResearch, West Grove, PA), and to Cdk5 was
AlexaFluor 488 (Molecular Probes, Leiden, Netherlands).
Statistical analysis Graphs and analyses were performed using GraphPad Prism
software. Statistical comparison among groups was made using one-way and two-way
ANOVA tests. A value of p<0.05 was considered significant. All results are
expressed as mean ± standard deviation.
RESULTS
p35 mRNA and protein levels increase in response to hypoxia and correlate with
decreased ATP levels and increased neuronal death.
Reduction of cellular ATP levels is an early event in response to periods of energy
deprivation. Hypoxia decreased intracellular ATP levels by approximately 70%
compared to normoxic controls within 2h but then stabilised till 6h (p <0.01, Fig 1A).
9At 24h ATP levels had decreased by approximately 85% (p <0.01) indicating
exceedingly low energy levels. Since cell survival is closely linked to ATP levels and
hypoxia has been shown to induce cell death we assessed LDH leakage, an
established index of neuronal death (Fig. 1B). Surprisingly, despite the dramatic fall
in ATP levels hypoxia did not significantly induce LDH release until after 6h
exposure when cell death increased by 6.610%±0.57 (p <0.05), compared to
normoxic values. An additional increase to 10.61%± 3.84 was observed by 24h
(p<0.01).
The effect of oxygen deprivation on the Cdk5/p35 complex was then assessed in
primary cortical neuronal cultures. Hypoxia rapidly upregulated p35 mRNA levels
with a peak (60 fold ± 5.20; p<0.01) observed at 2h (Fig. 1C). This increase was
transient, and mRNA levels rapidly returned to baseline after 4h of hypoxia. Increased
p35 protein levels paralleled the increase in mRNA (Fig. 1D). Quantification shows
p35 protein levels increased 1.8 fold (± 0.55; p<0.05) after 2h and remained elevated
at 4h  (1.53 fold ± 0.22; p<0.05) but were then significantly downregulated. Notably,
hypoxic exposure did not lead to production of p25, the p35 breakdown product. A
change in the electrophoretic mobility of p35 after 2h of hypoxia was also observed
suggesting protein dephosphorylation. Dephosphorylation was observed to be rapid,
occurring as early as 30 min, and reversible when neurons where reoxygenated (4h)
following 2h of hypoxia, as indicated by the detection of a higher molecular weight
band (Fig. 1E). These results imply that p35 phosphorylation is likely an early
signalling event tightly linked to alterations in oxygen levels.
Using immunocytochemistry we localised p35 throughout the neuronal soma and
neurites (Fig. 1F), however hypoxia did not affect p35 cellular distribution.
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Altogether, our results show that oxygen deprivation modulates p35 both at the
transcriptional and translational level and that such changes correlate with decreased
ATP levels and the first signs of neuronal death.  Nevertheless, despite the hypoxic
insult, p35 cleavage was not observed suggesting that calpain pathways are not
activated.
Cdk5 activity is upregulated by hypoxia
Similar to p35, peak induction of Cdk5 mRNA occurred at 2h of hypoxia (25.92 ±
7.87; p<0.01; Fig. 2A) and stayed elevated at 4h (11.75 ± 1.6; p<0.01) before
returning to baseline by 6h. In contrast Cdk5 protein levels were not affected by
hypoxia, remaining constant at all time points (Fig. 2B). Using a phosphorylation-
specific antibody that targets the Ser159 residue of Cdk5, a marker of protein
activation (Sharma et al., 1998), we observed a transient increase in phosphorylation
after 2h and 4h of hypoxia indicating increased Cdk5 activity (Fig. 2C). To confirm
this observation we performed in vitro kinase assays (Fig. 2D) and again Cdk5
activity increased at 2h and was elevated further by 4h. This was consistent with both
the phosphorylation state of Cdk5 and increased p35 levels, suggesting that Cdk5
activity is regulated by p35. Cdk5 activity was only transient and returned to basal
levels but remained detectable at 24h even in the absence of p35 indicating that other
mechanisms may compensate for loss of p35.
Immunostaining analysis (Fig. 2E) showed that under normoxic conditions Cdk5 is
mainly cytoplasmic but after 4h of hypoxia, when activity of Cdk5 is maximal,
increased localisation to the neuronal soma is clearly visible (Fig. 2E, arrows). The
mislocalisation of Cdk5 to the neuronal soma suggests possible interaction of the
kinase with different effectors.
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Cdk5 is necessary for Hif-1α stabilisation
Hif-1 is the main regulator of hypoxic responses. As expected Western blotting and
subsequent quantification demonstrate hypoxia mediated time-dependent
accumulation of Hif-1α  in neurons (Fig. 3A). Hif-1α stability and transcriptional
activity is regulated by posttranslational modifications such as phosphorylation.
Following sequence analysis we identified a potential Cdk5 phosphorylation site in
the Hif -1 sequence and more specifically within the inhibitory domain of Hif-1α
(Fig. 3B), suggesting that Hif-1α may be a Cdk5 substrate. To investigate whether
Cdk5 can associate with Hif-1α we performed co-immunoprecipitation experiments.
Cell extracts from both normoxic and hypoxic neurons were immunoprecipitated with
Cdk5 and immunoblotted with a Hif-1α antibody (Fig. 3C). Supernatant controls
(ctrl) as well as beads only controls (B) were also included. Association of Cdk5 with
basal Hif-1α levels were detected both in normoxia as well as hypoxia. Interestingly
however this interaction did not seem to be modulated by hypoxia.
To further explore Hif-1α  modulation by Cdk5, neurons were treated with
roscovitine, a Cdk5-specific pharmacological inhibitor (20µM)(Slevin and Krupinski,
2009). Exposure to roscovitine immediately prior to hypoxic exposure attenuated
temporal accumulation of Hif-1α during hypoxia (Fig. 3D). Quantification confirmed
a 50% downregulation of Hif-1α by 6h (Fig. 3D, p < 0.01). To elucidate whether the
observed decrease of Hif-1α induction by Cdk5 inhibition was transient, neurons were
exposed to roscovitine during prolonged hypoxia (24h-48h). Remarkably, roscovitine
treatment completely abolished Hif-1α  accumulation after 24h (Fig.3E, p< 0.001).
Notably, roscovitine treatment did not affect Hif-1α mRNA levels (data not shown),
suggesting that cdk5 regulates Hif-1α  at the post-translational level.
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Immunocytochemistry further confirmed this result (Fig 3F). In normoxia Hif-1α is
not detected in neurons either in the absence or presence of roscovitine. Hif-1α is
strongly induced under hypoxic conditions and is localised to the cell nucleus after 6h
exposure. Strikingly, roscovitine treatment causes marked loss of HIF-1α nuclear
accumulation in virtually all neurons. Thus, this data demonstrates that Cdk5 activity
is essential for Hif-1α stabilization.
Cdk5 inhibition downregulates Hif-1-mediated signalling pathways and
increases cell death during chronic hypoxia
Cdk5 inhibition attenuated Hif-1α accumulation suggesting an impact on Hif-1-
mediated signaling pathways. To assess the effect of Cdk5 inhibition on Hif-1
downstream signaling pathways Glut-1 and Epo mRNA levels were assessed by
quantitative RT-PCR. As expected, 24h hypoxia upregulated both Glut-1 and Epo
mRNA levels in a time-dependent manner in control cells (Fig. 5A, 5B). Roscovitine
exposure for 6h and 24h decreased Glut-1 mRNA expression compared to controls by
approximately 40% (p<0.05 ). Interestingly, application of roscovitine completely
abolished Epo mRNA levels (p <0.001) after 24h drug application. Thus inactivation
of Cdk5 inhibits Hif-1 stabilization and subsequent activation of downstream
signaling pathways.
Involvement in regulation of Hif-1α-inducible pathways suggested a role for Cdk5 in
hypoxic neuronal survival. Hypoxia alone induced only limited cell death for the first
24h of exposure that significantly increased to 15.74% ± 1.71 at 36h and 26.54%
±1.58 at 48h (Fig. 4C). Roscovitine treatment did not affect neuronal survival in
normoxic cultures (up to 48h) or cells exposed to the drug for up to 24h hypoxia
compared to controls. However extended drug treatment significantly induced cell
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death (27.46% ±8.43 and 38.27% ± 3.69 after 36h and 48h respectively, (p <0.01)
compared with hypoxia alone. Thus sustained Cdk5 inhibition renders neurons more
vulnerable to prolonged hypoxic insult.
DISCUSSION
The Cdk5/p35 complex plays a crucial role in regulating neuronal survival during
both development and disease (Cheung and Ip, 2004). Nevertheless, the mechanisms
by which Cdk5 contributes to neuronal survival are largely unknown. Li et al., (Li et
al., 2002) reported a key role for the kinase in promoting neuronal survival via
negative regulation of the pro-apoptotic JNK3 pathway in UV-exposed neurons and a
study by Wang et al., (Wang et al., 2006) suggested that basal Cdk5 activity is
required to protect hippocampal neurons from serum deprivation via activation of Bcl-
2. Conversely, other evidence suggests that abnormal Cdk5 activation is neurotoxic
leading to apoptosis under both physiological and pathological conditions (Shelton
and Johnson, 2004). With this study we provide new evidence that Cdk5, and its
neuronal activator p35 shape the neuronal hypoxic response and contribute to Hif-
1α modulation.
The first evidence of a role for the Cdk5/p35 complex in neuronal responses to
oxygen deprivation came from research in Drosophila (Ma and Haddad, 1999). Since
then a number of studies have reported upregulation of the complex in models of
ischemia both in vivo and in vitro (Hayashi et al., 1999; Mitsios et al., 2007; Strocchi
et al., 2003). However how oxygen deprivation alone specifically regulates the
complex in mammalian cells has not been demonstrated. Our results show that
hypoxia distinctly modulates both components of the complex, in agreement with
another study showing increased activation of Cdk5 in neuroblastoma cells subjected
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to chemical oxidative stress (Strocchi et al., 2003). Thus oxygen deprivation and
ischemia both directly regulate Cdk5, suggesting a role for this kinase in determining
hypoxic neuronal function and survival.
Published data suggests that p35 mediates the protective properties of Cdk5 (Cheung
and Ip, 2004). On the other hand binding of Cdk5 to p25, the product of p35 cleavage
by calpain, is required to render Cdk5 a pro-death protein. Prolonged activation and
mislocalisation of the protein as a result of binding to p25 leads to cytoskeletal
damage and apoptosis - an event linked to Alzheimer’s disease (Patrick et al., 1999).
It is believed that phosphorylated p35 is more resistant to calpain cleavage as opposed
to unphosphorylated p35 which is easily cleaved to p25 when calpain is activated
(Saito et al., 2003). Although hypoxia did not affect p35 localisation, a change in the
electrophoretic mobility of the protein was noted suggesting an altered
phosphorylation state. However hypoxic-induced dephosphorylation of p35 did not
lead to p25 formation in our study, indicating that calpain pathways were not
activated. Thus the role of p35 during hypoxic exposure remains intriguing and
deserves further investigation.
The localisation of Cdk5 is also an important feature of neurotoxicity that could
determine neuronal fate (O'Hare et al., 2005). In vitro, both Cdk5 and p35 have been
localised to the soma and along neurites (Nikolic et al., 1998; Qu et al., 2007) as well
as the nucleus (O'Hare et al., 2005). Although p35 localisation was unaffected,
hypoxia caused redistribution of Cdk5 from over the entire cell to mainly the neuronal
soma, suggesting an altered function for the kinase and possible interaction with
aberrant proteins. The mechanism behind this translocation is till now elusive.
Notably, studies have shown nuclear translocation of Cdk5 can result in modulation of
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transcription factors that are involved in cell death pathways (Cheung and Ip, 2004;
O'Hare et al., 2005), evidence that may support an interaction with Hif-1.
Cellular responses to reduced oxygenation are mainly controlled by the transcription
factor Hif-1 (Fandrey et al., 2006; Hopfl et al., 2003). Regulation of Hif-1 protein
levels is complex and involves multiple pathways. Several reports have documented
regulation of Hif-1 phosphorylation by a number of kinases including the glycogen-
synthase-kinase3 (GSK3) and MAPKs in oxygen-dependent and -independent
manners (Antoniou et al., 2010; Brahimi-Horn et al., 2005). For instance, Hif-1α
phosphorylation by GSK3, another key kinase in neurodegeneration, is involved in
Hif-1α ubiquitination and subsequent degradation. The identification of a putative
Cdk5 phosphorylation site (SPDR) within the inhibitory domain of the Hif-1α protein
sequence suggests that Cdk5 could phosphorylate Hif-1α directly thus influencing its
accumulation. Indeed our experiments confirmed that Cdk5 interacts with basal Hif-
1α  in neurons. Furthermore pharmacological inhibition of Cdk5 completely
attenuated Hif-1α expression providing additional evidence for Cdk5-dependent Hif-1
regulation. The disruption of HIF-1α regulation would have significant consequences
on cell survival since induction of target gene expression, downstream signaling and
therefore subsequent hypoxic adaptation would also be abrogated. Accordingly, we
observed a reduction of cell survival with prolonged hypoxic exposure and
significantly reduced expression of two important target genes, namely Epo and Glut-
1, after treatment with roscovitine confirming impairment of the hypoxic signaling
cascade. Other in vitro models have also shown that neurons exposed to hypoxia
significantly upregulate Glut-1 and Epo (Genc et al., 2004) mRNA and protein levels.
Glut-1 is associated with compensatory changes targeted at protecting glucose
delivery to fuel cellular energy metabolism and thus is crucial for cell survival.
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Pretreatment with Epo prevents neuronal death in in vitro models of hypoxia and
reduces ischemic damage in various animal models of stroke (Jin et al., 2000; Liu et
al., 2006). The correlation of reduced expression of both Epo and Glut-1 with
increased cell death emphasizes the importance of Cdk5 activity in hypoxic
adaptation. Taken together our results provide strong evidence that in the absence of
Cdk5 activity, stabilization of Hif-1 is abrogated and continued suppression of Hif-1
signalling results in increased neuronal death. Thus similar to other studies (Strocchi
et al., 2003), we propose that although increased activity of Cdk5 that results from
cleavage of p35 to p25 might be detrimental,  p35-mediated Cdk5 activity and
signalling is required for neuronal hypoxic adaptation.
Although more studies are required it is also tempting to speculate that the interaction
between Cdk5 and Hif-1 may reflect an involvement of the cytoskeleton in the
neuronal hypoxic response. Cdk5 is a major regulator of the actin neuronal
cytoskeleton and hypoxic induced alterations of the cellular cytoskeleton have been
previously described (Bouvry et al., 2006; Friedman et al., 1998). In line with these
observations we observed hypoxic-induced alterations in the F-actin neuronal
cytoskeleton, while tubulin - another important cytoskeletal component - was less
affected (data not shown). Further studies are currently underway to explore this
possibility.
This study is the first to present evidence that Cdk5, a key player in neurodegenerative
disorders, is involved in regulation of Hif-1α possibly via a direct interaction.
Considering the importance of the Cdk5/p35 complex in neurodegenerative disorders,
and the fact that hypoxia is an ongoing state in many of these diseases, it is crucial to
determine whether the identified mechanism is universal or restricted to neurons.
17
Clearly, further investigation of the interaction between Cdk5 and Hif-1 is required to
shed more light on a new pathway that may control neuronal survival.
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FIGURE LEGENDS
Fig. 1. p35 is regulated by hypoxia at the transcriptional and translational level
and correlates with decreased ATP levels and increased neuronal death
A) Intracellular ATP levels are significantly reduced during hypoxic exposure. A 70%
reduction is observed already after 2h that further decreases at 24h. B) Hypoxia
decreases neuronal survival. Neuronal death was measured with the LDH assay. A
time dependent increase in cell death (10-15%) is observed during hypoxic exposure.
* and ** denotes p < 0.05 and p < 0.01 respectively. C) Real-time PCR demonstrates
a large but transient increase in p35 mRNA expression after 2h of hypoxia, which
drops to normoxic levels by 4h. D) Representative Western blot for p35 shows protein
levels are increased by hypoxic exposure but later down regulated. Quantification
shows a 1.8 fold ± 0.5 increase in p35 expression after 2h of hypoxia. p35 levels
remain above normoxic ones after 4h of hypoxia (1.5 fold ± 0.2), but fall below
normoxic levels by 24h (0.17 fold ± 0.1). A change in p35 mobility after 2h hypoxic
exposure is also observed but p25 is not detected. E) Western blot analysis shows
electrophoretic mobility of p35 already increases by 30 min of hypoxia and is
reversible with reoxygenation. Data is representative of at least 3 independent
experiments, * and ** denotes p < 0.05 and p < 0.01 respectively. All blots are
normalised to Tuj-1. F) p35 immunocytochemistry shows protein localisation is
unaltered by hypoxic exposure. In all cases p35 localised to the neuronal soma and
dendrites both in normoxia and hypoxia. Nuclei were co-stained with the nuclear
marker DAPI. Magnification: 40X.
Fig. 2. Activity of Cdk5 is induced by hypoxia.
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A) Real-time PCR shows that Cdk5 mRNA levels are significantly but transiently
induced after 2h (24.73 fold ± 5.3) and 4h (10.95 fold ± 1.8) of hypoxia. B)
Representative Western blot analysis shows that Cdk5 protein levels are not affected
by hypoxia. C) Representative Western blot showing a transient increase in
phosphorylated Cdk5 following 2h and 4h of hypoxia. D) Kinase activity assays
(using Histone H1) show transient upregulation of Cdk5 activity by hypoxia before
returning to baseline. Blots are representative of at least 3 independent experiments,
** denotes a p value of < 0.01 compared to normoxic controls. E) Neuronal
localization of Cdk5 is altered by hypoxic exposure. Representative
immunocytochemistry photomicrographs show nuclear accumulation of Cdk5 to the
neuronal soma after 4h of hypoxia (see arrows) and insert shows magnified images.
Nuclei were co-stained with the nuclear marker DAPI.  Magnification: 40X.
Fig. 3. Cdk5 inhibition attenuates Hif-1α hypoxic induction.
A) Representative Western blot shows hypoxia induces time-dependent induction of
Hif-1α in neurons. Quantification shows that Hif-1α is significantly induced
following 2h hypoxia and continues accumulating up to 24h (** and *** denotes p <
0.01 and p < 0.001 respectively compared to normoxic controls). B) Within the Hif-1
protein sequence a putative Cdk5 phosphorylation motif (SPDR) has been identified.
C) Immunoprecipitation for Cdk5 was performed on normoxic (Nx) and hypoxic (Hx,
2h exposure) neuronal culture lysates. The samples were then immunoblotted for Hif-
α and Cdk5. A representative experiment shows that Cdk5 interacts with Hif-1α basal
levels both under normoxic and hypoxic conditions (Ctrl= input control lanes; B=
beads only control). D) Representative Western blot showing that roscovitine
application treatment (R, 20µΜ )  during hypoxic exposure inhibits Hif-
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1 α accumulation compared to control (C) cells. Quantification demonstrates
significant downregulation (50%) of Hif-1α  hypoxic induction by 6h. E)
Representative Western blot and quantification of Hif-1α induction during prolonged
hypoxia and after Cdk5 inhibition. Roscovitine application completely abolishes Hif-
1α accumulation by 24h of hypoxia. Blots are representative of at least 3 independent
experiments; ** and *** denotes p < 0.01 and p < 0.001 respectively. Open bars
represent controls, black bars represent roscovitine treated samples. F)
Immunocytochemistry demonstrates shows that nuclear localization of Hif-1α  in
neurons is abrogated by roscovitine treatment. Hif-1α is virtually undetectable under
normoxic conditions in presence or absence of roscovitine. Hypoxic exposure results
in strong Hif-1α induction and localization to the nucleus in control cells. Notably,
treatment with the Cdk5 inhibitor markedly reduces this accumulation already at 6h.
Nuclei were co-stained with the nuclear marker DAPI. Magnification: 40X.
Fig. 4.  Cdk5 inhibition abrogates Hif-1 downstream signalling and increases
neuronal death during hypoxia.
The effect of roscovitine treatment on hypoxic induction of Epo and Glut-1 mRNA
levels was assessed by RT-PCR. A) Hypoxia induces Glut-1 mRNA expression time
dependently. Roscovitine treatment has no effect up to 4h but attenuates reduces
hypoxic-induced Glut-1 expression after 6h. B) 24h hypoxic exposure induces Epo
mRNA expression. Roscovitine application completely attenuates hypoxic-induced
Epo mRNA induction at 24h. At least 3 independent experiments were performed and
all values are normalised to 28sRNA and normoxic controls (* and *** denote p <
0.05 and p < 0.001 respectively compared to normoxic controls) ). Open bars
represent controls, black bars represent roscovitine treated samples. C) LDH assay
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was performed on media from roscovitine-treated neurons exposed to hypoxia.
Hypoxic exposure alone caused a time-dependent increase in cell death. Roscovitine
treatment significantly enhanced cell death in hypoxic, but not normoxic, cultures
after prolonged hypoxic exposure (** denotes a p < 0.01 compared to normoxic
control).
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